Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, Y and W135 conjugate vaccine
- Development stage
- Approved
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The meningococcal group A, C, Y and W135 conjugate vaccine developed by Amvex Biopharmaceuticals (a subsidiary of Aim Vaccine) is a quadrivalent vaccine designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. The vaccine consists of capsular polysaccharide antigens from each of the four serogroups, each individually conjugated to a carrier protein, typically CRM197 (a non-toxic mutant of diphtheria toxin). This conjugation process converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which significantly enhances immunogenicity, particularly in infants and young children, and induces long-term immunological memory. The vaccine is primarily indicated for active immunization against meningococcal infection and is currently in late-stage clinical development in China.
- Brand names
- MenveoNimenrixMenQuadfi
- Other names
- MenACWY conjugate vaccineQuadrivalent meningococcal conjugate vaccineMeningococcal polysaccharide conjugate vaccine (Groups A, C, Y and W135)
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, Y and W135 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, Y and W135 conjugate vaccine.